Reply to Stefano Fanti, Bernd Krause, Wolfgang Weber, et al's Letter to the Editor re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83

European Urology

Volumn 60, Issue 5, 2011, Pages

  Mottet, Nicolas ^a   Bellmunt, Joaquim ^b   Bolla, Michel ^c   Joniau, Steven ^d   Mason, Malcolm ^e   Matveev, Vsevolod ^f   Schmid, Hans Peter ^g   Van Der Kwast, Theo ^h   Wiegel, Thomas ⁱ   Zattoni, Filiberto ^j   Heidenreich, Axel ^k  

^a Clinique Mutualiste de la Loire   (France)

^b HOSPITAL DEL MAR   (Spain)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e VELINDRE CANCER CENTRE   (United Kingdom)

^f INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^g Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j UNIVERSITY OF PADOVA   (Italy)

^k UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY;

EID: 80053315425     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.010     Document Type: Letter

References (10)

1. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
2. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. European Association of Urology Web site. www.uroweb.org/guidelines.
3. P. Castellucci, C. Fuccio, and C. Nanni Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med 50 2009 1394 1400
4. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. In press. DOI:10.1016/j.urolonc.2010.08.008.
5. M. Picchio, A. Briganti, and S. Fanti The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer Eur Urol 59 2011 51 60
6. L. Rinnab, F.M. Mottaghy, and N.M. Blumstein Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer BJU Int 100 2007 786 793 (Pubitemid 47360183)
7. M. Cimitan, R. Bortolus, and S. Morassut [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 2006 1387 1398 (Pubitemid 44885404)
8. G. Giovacchini, M. Picchio, and A. Briganti [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging J Urol 184 2010 938 943
9. M. Souvatzoglou, B.J. Krause, and A. Pürschel Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer Radiother Oncol 99 2011 193 200
10. 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38 2011 55 63